You are here

Exhaled breath drug detection using differential mobility spectrometry

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R42DA049655-01
Agency Tracking Number: R42DA049655
Amount: $509,219.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDA
Solicitation Number: PA18-935
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-09-01
Award End Date (Contract End Date): 2021-02-28
Small Business Information
Newton, MA 02466-2006
United States
DUNS: 116996742
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (781) 917-3366
Business Contact
Phone: (781) 366-7079
Research Institution
GAINESVILLE, FL 32611-5500
United States

 Nonprofit College or University

Project Summary
This proposal seeks to expand upon breath analysis technology that is being actively studied as the focus of NIH
grant #6R42DA049655-02 and leverage this technology for rapid COVID-19 diagnostics. There is a dire need
for sensitive and specific diagnostic tests for COVID-19 that can be performed quickly. The differential mobility
spectrometry (DMS) breath analysis technology currently under investigation for drug detection may be adapted
to fill this void.
During this supplement we will perform a biomarker discovery effort to determine the exhaled breath molecular
species most suitable for use as a COVID-19 biomarker. Once a target species has been identified, methods of
capture that can be implemented within the safety paradigm governing COVID-19 testing will be investigated.
We will also initiate conversation with the FDA and develop an FDA approval strategy to expedite the deployment
of a future breath based COVID-19 diagnostic instrument based upon the technology being studied under this
administrative supplement’s parent grant.Project Narrative
The proposed administrative supplement consists of an effort to leverage the exhaled breath analysis
technology, being investigated under the parent grant, for COVID-19 detection. The work proposed in this
administrative supplement will identify exhaled breath biomarkers with promising potential for clinical use as a
COVID-19 diagnostic. Once a biomarker target is identified we will investigate methods of trapping this molecular
species suitable for enhanced biosafety as required for COVID-19 activities. Finally, we will initiate discussions
with the FDA and develop an approach for obtaining FDA approval for a COVID-19 diagnostic technique based
upon the microAnalyzer instrument being investigated under the parent grant.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government